What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Pharmacology
- Anesthesia
Tony L. Yaksh focuses on Pharmacology, Anesthesia, Nociception, Spinal cord and Morphine.
In his study, Antagonist is inextricably linked to Agonist, which falls within the broad field of Pharmacology.
His research in Anesthesia intersects with topics in Hyperalgesia and Allodynia.
His study with Nociception involves better knowledge in Internal medicine.
In his work, Microdialysis is strongly intertwined with Glutamate receptor, which is a subfield of Spinal cord.
His Morphine research also works with subjects such as
- -Naloxone that intertwine with fields like Opiate,
- Periaqueductal gray that connect with fields like Microinjection.
His most cited work include:
- Quantitative assessment of tactile allodynia in the rat paw. (5194 citations)
- Chronic catheterization of the spinal subarachnoid space. (2092 citations)
- Analgesia mediated by a direct spinal action of narcotics. (798 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Anesthesia, Pharmacology, Internal medicine, Endocrinology and Nociception.
The Anesthesia study combines topics in areas such as Allodynia and Spinal cord.
His work carried out in the field of Spinal cord brings together such families of science as Central nervous system and Anatomy.
Tony L. Yaksh studies Pharmacology, namely Morphine.
His Morphine research integrates issues from -Naloxone and Opiate.
His Endocrinology study integrates concerns from other disciplines, such as Neuropeptide, Capsaicin, Cholecystokinin and Enkephalin.
He most often published in these fields:
- Anesthesia (40.95%)
- Pharmacology (34.37%)
- Internal medicine (28.14%)
What were the highlights of his more recent work (between 2010-2021)?
- Anesthesia (40.95%)
- Pharmacology (34.37%)
- Allodynia (8.42%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Anesthesia, Pharmacology, Allodynia, Hyperalgesia and Neuropathic pain.
He combines subjects such as Surgery and Spinal cord with his study of Anesthesia.
The concepts of his Pharmacology study are interwoven with issues in Nociception, Inflammation, Antagonist, Substance P and Degranulation.
As part of one scientific family, Tony L. Yaksh deals mainly with the area of Allodynia, narrowing it down to issues related to the TLR4, and often Microglia.
Tony L. Yaksh has included themes like Threshold of pain and Immunology in his Hyperalgesia study.
Tony L. Yaksh works mostly in the field of Neuropathic pain, limiting it down to concerns involving Chronic pain and, occasionally, Bioinformatics.
Between 2010 and 2021, his most popular works were:
- Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. (215 citations)
- A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. (122 citations)
- The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines (113 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Enzyme
- Pharmacology
Tony L. Yaksh mainly investigates Anesthesia, Pharmacology, Allodynia, Hyperalgesia and Chronic pain.
His Anesthesia research is multidisciplinary, relying on both Pharmacokinetics, Toxicity and Nociception.
His Nociception study incorporates themes from Analgesic, Tachykinin receptor 1 and Opioid.
His Pharmacology research includes themes of NAV1, Sodium channel, Substance P, Calcium channel and Spinal cord.
His biological study spans a wide range of topics, including Nociceptor and Postsynaptic potential.
He interconnects Internal medicine, Signal transduction and Endocrinology in the investigation of issues within Immunology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
